Technical Analysis for RETA - Reata Pharmaceuticals, Inc. - Class A

Grade Last Price % Change Price Change
grade B 87.56 -4.57% -4.19
RETA closed down 4.57 percent on Friday, September 21, 2018, on 1.65 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical RETA trend table...

Date Alert Name Type % Chg
Sep 21 20 DMA Support Bullish 0.00%
Sep 21 Bollinger Band Squeeze Range Contraction 0.00%
Sep 21 Multiple of Ten Bearish Other 0.00%
Sep 21 BB Squeeze Started Range Contraction 0.00%
Sep 20 20 DMA Support Bullish -4.57%
Sep 20 Multiple of Ten Bullish Other -4.57%
Sep 19 20 DMA Support Bullish 2.39%
Sep 19 Multiple of Ten Bearish Other 2.39%
Sep 19 Overbought Stochastic Strength 2.39%
Sep 19 Down 3 Days in a Row Weakness 2.39%

Older signals for RETA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company focuses on drugs with novel mechanisms of action that modulate regulatory proteins called transcription factors. Its lead product candidates include bardoxolone methyl and RTA 408, which are members of a class of small molecules called antioxidant inflammation modulators. It is involved in LARIAT, a Phase II study of bardoxolone methyl for the treatment of pulmonary arterial hypertension and pulmonary hypertension due to interstitial lung disease. RTA 408 is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia and mitochondrial myopathies. Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.
Is RETA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 93.94
52 Week Low 19.31
Average Volume 487,626
200-Day Moving Average 39.8426
50-Day Moving Average 74.2038
20-Day Moving Average 85.939
10-Day Moving Average 88.436
Average True Range 5.3151
ADX 36.91
+DI 22.3183
-DI 17.4765
Chandelier Exit (Long, 3 ATRs ) 77.9947
Chandelier Exit (Short, 3 ATRs ) 88.6853
Upper Bollinger Band 94.6263
Lower Bollinger Band 77.2517
Percent B (%b) 0.59
BandWidth 20.217363
MACD Line 4.783
MACD Signal Line 5.4149
MACD Histogram -0.6319
Fundamentals Value
Market Cap 2.29 Billion
Num Shares 26.1 Million
EPS -1.06
Price-to-Earnings (P/E) Ratio -82.60
Price-to-Sales 15.55
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 99.26
Resistance 3 (R3) 99.35 95.55 97.31
Resistance 2 (R2) 95.55 92.57 95.50 96.66
Resistance 1 (R1) 91.55 90.73 89.65 91.46 96.01
Pivot Point 87.75 87.75 86.80 87.70 87.75
Support 1 (S1) 83.75 84.77 81.85 83.66 79.11
Support 2 (S2) 79.95 82.93 79.90 78.46
Support 3 (S3) 75.95 79.95 77.81
Support 4 (S4) 75.86